BioPorto aktie (BIOPOR) | Pressmeddelande

BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024

GlobeNewswire • 14 Nov 08:50

BioPorto A/S to Host Third Quarter 2024 Earnings Webcast

GlobeNewswire • 12 Nov 09:57

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.

GlobeNewswire • 08 Nov 17:03

Grant of Warrants

GlobeNewswire • 04 Nov 18:44

First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital

First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospit...

GlobeNewswire • 29 Oct 08:56

BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests

GlobeNewswire • 28 Oct 16:26

BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference

GlobeNewswire • 23 Oct 17:15

BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL

GlobeNewswire • 22 Oct 08:04

BioPorto A/S Announces Changes to the US Commercial Organization

GlobeNewswire • 21 Oct 17:15

BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study

GlobeNewswire • 10 Oct 16:17

Første 6 måneder af 2024: Fortsat stærk vækst i salget af NGAL-tests i USA og fokuseret eksekvering af alle elementer i BioPortos strategi

GlobeNewswire • 15 Aug 08:58

BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024

GlobeNewswire • 15 Aug 08:37

BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting

GlobeNewswire • 07 Aug 13:04

BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms

BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algor...

GlobeNewswire • 30 Jul 17:15

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

GlobeNewswire • 29 Jul 16:35

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

GlobeNewswire • 26 Jul 17:15

Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker

GlobeNewswire • 17 Jul 17:50

Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury

GlobeNewswire • 11 Jul 17:15

Grant of Warrants

GlobeNewswire • 04 Jul 17:54

BioPorto confirms market acceptance of NGAL products with US standing order.

GlobeNewswire • 01 Jul 17:30

Managers’ transactions

GlobeNewswire • 24 Jun 09:55

Changes of number of shares and votes in BioPorto A/S

GlobeNewswire • 24 Jun 09:52

Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.

Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.

GlobeNewswire • 18 Jun 08:14

BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.

GlobeNewswire • 17 Jun 19:04

BioPorto A/S Appoints Chief Financial Officer

GlobeNewswire • 30 May 14:17

First Quarter 2024: Strong growth in US sales of The NGAL Test

GlobeNewswire • 08 May 08:21

BioPorto A/S Appoints President and CEO of BioPorto Inc.

GlobeNewswire • 07 May 13:10

BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting

GlobeNewswire • 02 May 13:53

Resolutions of Annual Geneal Meeting

GlobeNewswire • 30 Apr 15:46

Grant of warrants

GlobeNewswire • 23 Apr 19:20

BioPorto A/S Appoints Chief Legal Officer

GlobeNewswire • 10 Apr 13:22

New Board Candidate for the upcoming Annual Geneal Meeting

GlobeNewswire • 05 Apr 15:46

Notice convening the Annual General Meeting in BioPorto A/S

GlobeNewswire • 04 Apr 11:07

Correction: BioPorto Announces Annual Results for 2023

GlobeNewswire • 04 Apr 09:43

BioPorto Announces Annual Results for 2023

GlobeNewswire • 04 Apr 08:29

BioPorto A/S to Host Annual Earnings Webcast

GlobeNewswire • 02 Apr 10:47

BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer

GlobeNewswire • 02 Apr 07:54

BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026

GlobeNewswire • 22 Feb 07:31

Roche Diagnostics and BioPorto expand collaboration

GlobeNewswire • 20 Feb 08:28

BioPorto A/S to host investor meetings on 22 February 2024

GlobeNewswire • 19 Feb 07:41

BioPorto implements changes to the Executive Management.

GlobeNewswire • 09 Jan 19:42

Managers’ transactions

GlobeNewswire • 09 Dec 2023 18:12

FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI)

GlobeNewswire • 08 Dec 2023 17:02

BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år

BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder t...

GlobeNewswire • 08 Dec 2023 08:13

BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years

BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Month...

GlobeNewswire • 07 Dec 2023 22:22

Resignation of Director

GlobeNewswire • 04 Dec 2023 20:00

BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference

GlobeNewswire • 01 Nov 2023 17:40

BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023

GlobeNewswire • 01 Nov 2023 08:31

BioPorto provides interim Q3 results and revised 2023 Financial Guidance.

GlobeNewswire • 31 Oct 2023 15:17

BioPorto A/S to Host Third Quarter 2023 Earnings Webcast and Analyst Call

GlobeNewswire • 20 Oct 2023 18:14

Grant of Warrants

GlobeNewswire • 22 Sep 2023 18:59

BioPorto Initiates Search for new CFO as Neil Goldman Resigns

GlobeNewswire • 19 Sep 2023 15:16

BioPorto Provides Update on NGAL Test Regulatory Pathway

GlobeNewswire • 11 Sep 2023 08:30

BioPorto to Participate in Upcoming Investor Conferences

GlobeNewswire • 28 Aug 2023 17:32

BioPorto Announces Interim Results for the First Six Months of 2023

GlobeNewswire • 01 Aug 2023 08:48

BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call

GlobeNewswire • 07 Jul 2023 14:55

BioPorto Announces Submission of Response to FDA Additional Information Letter

GlobeNewswire • 29 Jun 2023 08:11

Managers’ transactions

GlobeNewswire • 28 Jun 2023 15:50

BioPorto A/S announces completion of rights issue; total number of shares and voting rights

GlobeNewswire • 23 Jun 2023 07:49

BioPorto A/S announces results of rights issue

GlobeNewswire • 21 Jun 2023 13:52

BioPorto A/S to Webcast with HCA and Nordnet regarding the ongoing rights issue

GlobeNewswire • 09 Jun 2023 15:38

BioPorto A/S initiates a rights issue with pre-emptive rights for its existing shareholders and proceeds of up to approximately DKK 59.4 million with approximately DKK 16.6 million pre-subscribed pursuant to advance commitments

BioPorto A/S initiates a rights issue with pre-emptive rights for its existing shareholders and proceeds of up to approximately DKK 59.

GlobeNewswire • 30 May 2023 17:27

Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act

Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of th...

GlobeNewswire • 23 May 2023 20:02

BioPorto Announces Interim Results for the First Three Months of 2023

GlobeNewswire • 10 May 2023 08:20

BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

GlobeNewswire • 03 May 2023 08:53

Resolutions of the General Meeting of BioPorto A/S

GlobeNewswire • 27 Apr 2023 16:14

Grant of Warrants

GlobeNewswire • 25 Apr 2023 22:12

Notice convening the Annual General Meeting in BioPorto A/S

GlobeNewswire • 05 Apr 2023 08:35

BioPorto Announces Annual Results for the Year ended December 31, 2022

GlobeNewswire • 30 Mar 2023 08:48

BioPorto Announces Financial Guidance for 2023

GlobeNewswire • 29 Mar 2023 22:51

US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.

US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop no...

GlobeNewswire • 29 Mar 2023 22:02

BioPorto A/S to Host Annual Earnings Webcast and Analyst Call

GlobeNewswire • 23 Mar 2023 19:34

BioPorto Provides a Business Update

GlobeNewswire • 15 Mar 2023 18:40

Grant of warrants

GlobeNewswire • 16 Feb 2023 22:15

BioPorto adds Dr. Tabari Baker as VP of Global Medical Affairs

GlobeNewswire • 14 Feb 2023 16:48

Financial Calendar 2023

GlobeNewswire • 30 Dec 2022 15:34

Grant of Warrants

GlobeNewswire • 08 Dec 2022 18:47

BioPorto adds Mr. Nis Kruse as EVP of Strategic Partnerships and GM of EMEA & APAC

GlobeNewswire • 05 Dec 2022 18:52

BioPorto adds Mr. Nis Kruse as EVP of Strategic Partnerships and GM of EMEA & APAC

GlobeNewswire • 05 Dec 2022 18:47

Resolutions of the Extraordinary General Meeting of BioPorto A/S

GlobeNewswire • 23 Nov 2022 09:36

Correction: BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

GlobeNewswire • 10 Nov 2022 20:51

BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

GlobeNewswire • 10 Nov 2022 20:27

BioPorto Announces Interim Results for the First Nine Months of 2022

GlobeNewswire • 09 Nov 2022 08:05

BioPorto Announces Interim Results for the First Nine Months of 2022

GlobeNewswire • 09 Nov 2022 08:01

BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

GlobeNewswire • 03 Nov 2022 17:05

BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

GlobeNewswire • 03 Nov 2022 17:00

NOTICE CONVENING THE EXTRAORDINARY GENERAL MEETING

GlobeNewswire • 01 Nov 2022 15:00

Update: BioPorto Exhibiting NGAL Biomarker at ASN Kidney Week – Antibodies, ELISA kits, and Clinical Chemistry Assays for Early Drug Development and Clinical Research

Update: BioPorto Exhibiting NGAL Biomarker at ASN Kidney Week – Antibodies, ELISA kits, and Clinical Chemistry Assays for Early Drug Develop...

GlobeNewswire • 27 Oct 2022 21:03

BioPorto Exhibiting NGAL Biomarker at ASN Kidney Week – Antibodies, ELISA kits, and Clinical Chemistry Assays for Early Drug Development and Clinical Research

BioPorto Exhibiting NGAL Biomarker at ASN Kidney Week – Antibodies, ELISA kits, and Clinical Chemistry Assays for Early Drug Development and...

GlobeNewswire • 27 Oct 2022 20:00

BioPorto to Participate in H.C. Wainwright’s 24th Annual Global Investment Conference

GlobeNewswire • 08 Sep 2022 14:00

BioPorto to Participate in H.C. Wainwright’s 24th Annual Global Investment Conference

GlobeNewswire • 08 Sep 2022 14:00

BioPorto Announces Interim Results for the First Six Months of 2022

GlobeNewswire • 17 Aug 2022 08:23

BioPorto Announces Interim Results for the First Six Months of 2022

GlobeNewswire • 17 Aug 2022 08:20

BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

GlobeNewswire • 08 Aug 2022 17:05

BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

GlobeNewswire • 08 Aug 2022 17:05

BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.

BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.

GlobeNewswire • 28 Jun 2022 21:02

BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.

BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.

GlobeNewswire • 28 Jun 2022 20:59

Moderated Webcast with BioPorto’s Management

GlobeNewswire • 21 Jun 2022 17:00

Moderated webcast with BioPorto’s management

GlobeNewswire • 21 Jun 2022 17:00

BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director

BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr.

GlobeNewswire • 20 Jun 2022 08:15

Börskollen

För dig med koll på börsen

Pressmeddelanden från BioPorto

BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024

BioPorto A/S to Host Third Quarter 2024 Earnings Webcast

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

Grant of Warrants

First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital

BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests

BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference

BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL

BioPorto A/S Announces Changes to the US Commercial Organization

BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study

Første 6 måneder af 2024: Fortsat stærk vækst i salget af NGAL-tests i USA og fokuseret eksekvering af alle elementer i BioPortos strategi

BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024

BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting

BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker

Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury

Grant of Warrants

BioPorto confirms market acceptance of NGAL products with US standing order.

Managers’ transactions

Changes of number of shares and votes in BioPorto A/S

Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.

BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.

BioPorto A/S Appoints Chief Financial Officer

First Quarter 2024: Strong growth in US sales of The NGAL Test

BioPorto A/S Appoints President and CEO of BioPorto Inc.

BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting

Resolutions of Annual Geneal Meeting

Grant of warrants

BioPorto A/S Appoints Chief Legal Officer

New Board Candidate for the upcoming Annual Geneal Meeting

Notice convening the Annual General Meeting in BioPorto A/S

Correction: BioPorto Announces Annual Results for 2023

BioPorto Announces Annual Results for 2023

BioPorto A/S to Host Annual Earnings Webcast

BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer

BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026

Roche Diagnostics and BioPorto expand collaboration

BioPorto A/S to host investor meetings on 22 February 2024

BioPorto implements changes to the Executive Management.

Managers’ transactions

FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI)

BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år

BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years

Resignation of Director

BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference

BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023

BioPorto provides interim Q3 results and revised 2023 Financial Guidance.

BioPorto A/S to Host Third Quarter 2023 Earnings Webcast and Analyst Call

Grant of Warrants

BioPorto Initiates Search for new CFO as Neil Goldman Resigns

BioPorto Provides Update on NGAL Test Regulatory Pathway

BioPorto to Participate in Upcoming Investor Conferences

BioPorto Announces Interim Results for the First Six Months of 2023

BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call

BioPorto Announces Submission of Response to FDA Additional Information Letter

Managers’ transactions

BioPorto A/S announces completion of rights issue; total number of shares and voting rights

BioPorto A/S announces results of rights issue

BioPorto A/S to Webcast with HCA and Nordnet regarding the ongoing rights issue

BioPorto A/S initiates a rights issue with pre-emptive rights for its existing shareholders and proceeds of up to approximately DKK 59.4 million with approximately DKK 16.6 million pre-subscribed pursuant to advance commitments

Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act

BioPorto Announces Interim Results for the First Three Months of 2023

BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

Resolutions of the General Meeting of BioPorto A/S

Grant of Warrants

Notice convening the Annual General Meeting in BioPorto A/S

BioPorto Announces Annual Results for the Year ended December 31, 2022

BioPorto Announces Financial Guidance for 2023

US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.

BioPorto A/S to Host Annual Earnings Webcast and Analyst Call

BioPorto Provides a Business Update

Grant of warrants

BioPorto adds Dr. Tabari Baker as VP of Global Medical Affairs

Financial Calendar 2023

Grant of Warrants